EconomyLens.com
No Result
View All Result
Wednesday, March 25, 2026
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials
EconomyLens.com
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials
No Result
View All Result
EconomyLens.com
No Result
View All Result
Home Economy

Biden calls for lower prices of Ozempic, similar drugs

Thomas Barnes by Thomas Barnes
July 2, 2024
in Economy
Reading Time: 5 mins read
A A
0
41
SHARES
508
VIEWS
Share on FacebookShare on Twitter

US President Joe Biden and Senator Bernie Sanders accused pharma firms Novo Nordisk and Eli Lilly of "price gouging". ©AFP

Washington (AFP) – US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop “ripping off the American people.”

Related

War-linked power crunch pushes Sri Lanka to four-day week

AI making cyber attacks costlier and more effective: Munich Re

German business morale falls as war puts recovery on ice: survey

ECB won’t be ‘paralysed’ in face of energy shock: Lagarde

Middle East war: global economic fallout

In an article written with Senator Bernie Sanders, Biden said US patients pay several times more than those in Canada, Germany and Denmark for Novo Nordisk’s diabetes drugs Ozempic and Wegovy, which can also be used for weight loss. A one-month supply of Ozempic in the United States last year was $936, compared to $169 in Canada and $103 in Germany, according to one study.

Eli Lilly was also charging “unconscionably high prices” for Mounjaro, a drug similar to Ozempic. “Why should people in Burlington, Vermont, pay so much more than people in Copenhagen or Berlin for the same drug?” wrote Biden and Sanders, who chairs the Senate committee on health and education.

Such “price gouging” makes the drugs unaffordable to millions of Americans, they said. “If the prices of these drugs are not substantially reduced, they have the potential to bankrupt the American health care system,” Biden and Sanders wrote. “We will not allow that to happen.”

In a statement to AFP, Novo Nordisk said it takes “patient access and affordability very seriously,” adding it was “disappointed that a very difficult and complex problem is being oversimplified and mischaracterized for political purposes.” The cost of Ozempic and Wegovy has decreased approximately 40 percent since their launch, it added, while admitting: “Even when we lower our prices, patients in the United States often don’t receive the savings — this is a problem.”

Eli Lilly said it offers Mounjaro, marketed to diabetes patients, and Zepbound, sold as a weight loss drug, “for as low as $25 a month to those eligible for our savings card program.” “Comparing list prices in the United States to other countries ignores patient affordability programs and hundreds of billions of dollars in discounts and fees” paid to intermediaries by pharmaceutical companies “that should lower the costs of medicines for Americans, but unfortunately this system can drive prices higher,” Eli Lilly said in a statement to AFP.

High prices for prescription drugs have been a long-standing problem for American patients, and Biden has focused on lowering health care costs as part of his campaign for reelection in November. The piece in USA Today comes days after Biden’s weak performance during a televised presidential debate with Republican Donald Trump sparked sharp concern among Democrats.

© 2024 AFP

Tags: drug priceshealthcarepharmaceuticals
Share16Tweet10Share3Pin4Send
Previous Post

Vote-ready UK waits to scoop up Brexit boost

Next Post

US stocks back at records while European bourses retreat

Thomas Barnes

Thomas Barnes

Related Posts

Economy

Japan PM asks IEA to prepare additional ‘coordinated release’ of oil

March 25, 2026
Economy

Top WTO official sounds fertiliser warning over Middle East war

March 24, 2026
Economy

Middle East war: global economic fallout

March 25, 2026
Economy

War in the Middle East: latest developments

March 25, 2026
Economy

Australia, EU agree sweeping new trade pact eight years in the works

March 24, 2026
Economy

Australia, EU agree sweeping new trade pact

March 23, 2026
Next Post

US stocks back at records while European bourses retreat

Athens Acropolis introduces private visits for 5,000 euros

Amazon counts on 'grit and innovation' to meet AI surge

Markets track Wall St records as Powell revives rate hopes

0 0 votes
Article Rating
Subscribe
Notify of
guest
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
  • Trending
  • Comments
  • Latest

New York ruling deals Trump business a major blow

September 30, 2024

Elon Musk’s X fights Australian watchdog over church stabbing posts

April 21, 2024

Women journalists bear the brunt of cyberbullying

April 22, 2024

France probes TotalEnergies over 2021 Mozambique attack

May 6, 2024

New York ruling deals Trump business a major blow

96

Ghanaian finance ministry warns against fallout from anti-LGBTQ law

74

Shady bleaching jabs fuel health fears, scams in W. Africa

71

Stock markets waver, oil prices edge up

65

IEA chief says ‘ready’ to release more oil reserves if needed

March 25, 2026

German business morale falls as war puts recovery on ice: survey

March 25, 2026

ECB won’t be ‘paralysed’ in face of energy shock: Lagarde

March 25, 2026

Labubu maker Pop Mart’s shares fall 23% despite surging earnings

March 25, 2026
EconomyLens Logo

We bring the world economy to you. Get the latest news and insights on the global economy, from trade and finance to technology and innovation.

Pages

  • Home
  • About Us
  • Privacy Policy
  • Contact Us

Categories

  • Business
  • Economy
  • Markets
  • Tech
  • Editorials

Network

  • Coolinarco.com
  • CasualSelf.com
  • Fit.CasualSelf.com
  • Sport.CasualSelf.com
  • SportBeep.com
  • MachinaSphere.com
  • MagnifyPost.com
  • TodayAiNews.com
  • VideosArena.com
© 2025 EconomyLens.com - Top economic news from around the world.
No Result
View All Result
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials

© 2024 EconomyLens.com - Top economic news from around the world.